JPS Vol65 Supplement2 2015.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Role and Mechanisms of Action of Micrornas in Cancer Drug Resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6*
Si et al. Clinical Epigenetics (2019) 11:25 https://doi.org/10.1186/s13148-018-0587-8 REVIEW Open Access The role and mechanisms of action of microRNAs in cancer drug resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6* Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can regulate various target genes and are thus involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. Drug resistance in cancer chemotherapy is one of the main obstacles to curing this malignant disease. Statistical data indicate that over 90% of the mortality of patients with cancer is related to drug resistance. Drug resistance of cancer chemotherapy can be caused by many mechanisms, such as decreased antitumor drug uptake, modified drug targets, altered cell cycle checkpoints, or increased DNA damage repair, among others. In recent years, many studies have shown that miRNAs are involved in the drug resistance of tumor cells by targeting drug-resistance-related genes or influencing genes related to cell proliferation, cell cycle, and apoptosis. A single miRNA often targets a number of genes, and its regulatory effect is tissue-specific. In this review, we emphasize the miRNAs that are involved in the regulation of drug resistance among different cancers and probe the mechanisms of the deregulated expression of miRNAs. The molecular targets of miRNAs and their underlying signaling pathways are also explored comprehensively. A holistic understanding of the functions of miRNAs in drug resistance will help us develop better strategies to regulate them efficiently and will finally pave the way toward better translation of miRNAs into clinics, developing them into a promising approach in cancer therapy. -
Principles and Applications of Rabbit Models for Atherosclerosis Research
J Atheroscler Thromb, 2018; 25: 213-220. http://doi.org/10.5551/jat.RV17018 Review Principles and Applications of Rabbit Models for Atherosclerosis Research Jianglin Fan1, Yajie Chen1, Haizhao Yan1, Manabu Niimi1, Yanli Wang2 and Jingyan Liang3 1Department of Molecular Pathology, Faculty of Medicine, Graduate School of Medical Sciences, University of Yamanashi, Yamanashi, Japan 2Department of Pathology, Xi’an Medical University, Xi’an, China 3Research Center for Vascular Biology, Yangzhou University School of Medicine, Yangzhou, China Rabbits are one of the most used experimental animals for biomedical research, particularly as a bio- reactor for the production of antibodies. However, many unique features of the rabbit have also made it as an excellent species for examining a number of aspects of human diseases such as atherosclerosis. Rabbits are phylogenetically closer to humans than rodents, in addition to their relatively proper size, tame disposition, and ease of use and maintenance in the laboratory facility. Due to their short life spans, short gestation periods, high numbers of progeny, low cost (compared with other large ani- mals) and availability of genomics and proteomics, rabbits usually serve to bridge the gap between smaller rodents (mice and rats) and larger animals, such as dogs, pigs and monkeys, and play an important role in many translational research activities such as pre-clinical testing of drugs and diag- nostic methods for patients. The principle of using rabbits rather than other animals as an experi- mental model is very simple: rabbits should be used for research, such as translational research, that is difficult to accomplish with other species. Recently, rabbit genome sequencing and transcriptomic profiling of atherosclerosis have been successfully completed, which has paved a new way for researchers to use this model in the future. -
WO 2017/147196 Al 31 August 2017 (31.08.2017) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/147196 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: Kellie, E. [US/US]; 70 Lanark Road, Maiden, MA 02148 C12Q 1/68 (2006.01) (US). COLE, Michael, B. [US/US]; 233 1 Eunice Street, Berkeley, CA 94708 (US). YOSEF, Nir [IL/US]; 1520 (21) International Application Number: Laurel Ave., Richmond, CA 94805 (US). GAYO, En¬ PCT/US20 17/0 18963 rique, Martin [ES/US]; 115 Peterborough Street, Boston, (22) International Filing Date: MA 022 15 (US). OUYANG, Zhengyu [CN/US]; 15 Vas- 22 February 2017 (22.02.2017) sar Street, Medford, MA 02155 (US). YU, Xu [CN/US]; 6 Whittier Place, Apt. 16j, Boston, MA 02 114 (US). (25) Filing Language: English (74) Agents: KOWALSKI, Thomas, J. et al; Vedder Price English (26) Publication Language: P.C., 1633 Broadway, New York, NY 1001 9 (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 62/298,349 22 February 2016 (22.02.2016) US kind of national protection available): AE, AG, AL, AM, (71) Applicants: MASSACHUSETTS INSTITUTE OF AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, TECHNOLOGY [US/US]; 77 Massachusetts Ave., Cam BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, bridge, MA 02139 (US). THE REGENTS OF THE UNI¬ DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, VERSITY OF CALIFORNIA [US/US]; 1111 Franklin HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, Street, 12th Floor, Oakland, CA 94607 (US). -
1 Combined Effect of Anti-High-Mobility Group Box-1 Monoclonal Antibody and Peramivir Against Influenza a Virus-Induced Pneumoni
Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice Kazuki Hatayama1; Nobuyuki Nosaka1*; Mutsuko Yamada1; Masato Yashiro1; Yosuke Fujii1; Hirokazu Tsukahara1; Keyue Liu3; Masahiro Nishibori3; Akihiro Matsukawa4; Tsuneo Morishima1,2 1 Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2 Department of Pediatrics, Aichi Medical University, Japan 3 Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 4 Department of Pathology and Experimental Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 1 *Correspondence author: Nobuyuki Nosaka 2-5-1 Shikata-cho, Kita-ku, Okayama city, Okayama pref. 700-8558, Japan Tel: +81-86-235-7249 Email: [email protected] Shortened title: Anti-HMGB1 plus peramivir for influenza 2 ABSTRACT Human pandemic H1N1 2009 influenza virus causes significant morbidity and mortality with severe acute lung injury (ALI) due to excessive inflammatory reaction, even with neuraminidase inhibitor use. The anti-inflammatory effect of anti-high-mobility group box-1 (HMGB1) monoclonal antibody (mAb) against influenza pneumonia has been reported. In this study, we evaluated the combined effect of anti-HMGB1 mAb and peramivir against pneumonia induced by influenza A (H1N1) virus in mice. Nine-week-old male C57BL/6 mice were inoculated with H1N1 and treated with intramuscularly administered peramivir at 2 and 3 days post-infection (dpi). The anti-HMGB1 mAb or a control mAb was administered at 2, 3, and 4 dpi. Survival rates were assessed, and lung lavage and pathological analyses were conducted at 5 and 7 dpi. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Test Catalogue August 2019
Test Catalogue August 2019 www.centogene.com/catalogue Table of Contents CENTOGENE CLINICAL DIAGNOSTIC PRODUCTS AND SERVICES › Whole Exome Testing 4 › Whole Genome Testing 5 › Genome wide CNV Analysis 5 › Somatic Mutation Analyses 5 › Biomarker Testing, Biochemical Testing 6 › Prenatal Testing 7 › Additional Services 7 › Metabolic Diseases 9 - 21 › Neurological Diseases 23 - 47 › Ophthalmological Diseases 49 - 55 › Ear, Nose and Throat Diseases 57 - 61 › Bone, Skin and Immune Diseases 63 - 73 › Cardiological Diseases 75 - 79 › Vascular Diseases 81 - 82 › Liver, Kidney and Endocrinological Diseases 83 - 89 › Reproductive Genetics 91 › Haematological Diseases 93 - 96 › Malformation and/or Retardation Syndromes 97 - 107 › Oncogenetics 109 - 113 ® › CentoXome - Sequencing targeting exonic regions of ~20.000 genes Test Test name Description code CentoXome® Solo Medical interpretation/report of WES findings for index 50029 CentoXome® Solo - Variants Raw data; fastQ, BAM, Vcf files along with variant annotated file in xls format for index 50028 CentoXome® Solo - with CNV Medical interpretation/report of WES including CNV findings for index 50103 Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with sWGS 50104 large CNVs through sWGS Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with aCGH 750k 50122 large CNVs through 750k microarray Medical interpretation/report of WES in index, package including genome -
Improving Pipeline for the Development of Influenza Antivirals
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Improving Pipeline for the Development of Influenza Antivirals Michael W Wathen, Ph.D. Chief, Antiviral Advanced Development Influenza Division BARDA BARDA Influenza Antiviral Program Strategy Overview National Strategy Issues BARDA Strategy ASPR: Resilient People. Healthy Communities. A Nation Prepared. 2 Issues for Influenza Antivirals • Current therapies have narrow treatment window ─ Treatment within 48h of symptom onset for neuraminidase inhibitors ─ Can treatment window be expanded with novel antivirals having different mechanisms of action? • Constant threat of resistance ─ Value of M-2 blockers minimized by resistance ─ Heavy reliance on neuraminidase inhibitors ─ Few combination therapies unavailable • Limited options in U.S. for special populations ─ No IV formulations approved for patients on ventilators ─ No drugs approved for severely ill, hospitalized patients ─ Limited treatment options for pediatric patients ASPR: Resilient People. Healthy Communities. A Nation Prepared. 3 BARDA Influenza Antiviral Program Advanced Development Strategy 2005 National Strategy for Pandemic Influenza • Accelerate development, evaluation, approval and U.S.-based production of new influenza antiviral drugs Treatment Gap Issues • Special populations (pediatrics, severely ill hospitalized) Existing BARDA Advanced Development Projects • Fill critical unmet medical needs by expanding the utility of neuraminidase inhibitors •Peramivir •$235M contract with BioCryst awarded in 2007 •Development of IV peramivir in hospitalized patients •EUA designated by FDA during 2009 pandemic •First unapproved drug authorized for use under an EUA •Worldwide clinical program for licensure in U.S. •Laninamivir •$231M contract with Biota awarded in 2011 •Development of inhaled laninamivir in outpatient setting •Single-dose treatment course ASPR: Resilient People. -
Hydrophobic Amino-Terminal Pocket CD14 Reveals a Bent Solenoid with a the Crystal Structure of Human Soluble
The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket This information is current as Stacy L. Kelley, Tiit Lukk, Satish K. Nair and Richard I. of September 25, 2021. Tapping J Immunol 2013; 190:1304-1311; Prepublished online 21 December 2012; doi: 10.4049/jimmunol.1202446 http://www.jimmunol.org/content/190/3/1304 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/12/31/jimmunol.120244 Material 6.DC1 http://www.jimmunol.org/ References This article cites 87 articles, 45 of which you can access for free at: http://www.jimmunol.org/content/190/3/1304.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket Stacy L. -
Advancing the Development Pipeline for the Treatment of Influenza
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Advancing the Development Pipeline for the Treatment of Influenza Melissa Willis, Ph.D. Chief, Influenza Therapeutics Influenza Division BARDA Roadmap • What is our goal? • Where have we been? • Where are we going? • Why now? • What strategies we are pursuing to achieve the goal? ASPR: Resilient People. Healthy Communities. A Nation Prepared. 2 BARDA Influenza Antiviral Program Program Goal “Reduce morbidity and mortality in all patient populations during an influenza pandemic by supporting advanced development, evaluation, and approval of new influenza antiviral drugs” • Mission established in the 2005 National Strategy for Pandemic Influenza, HHS Pandemic Influenza Plan and the 2006 Implementation Plan for the National Strategy for Pandemic Influenza • Initial stockpiling goal and advanced development projects • Stockpile total of 81M treatment courses of influenza antiviral drugs • Advanced development of new antiviral drugs • New BARDA advanced development projects are focused on developing drugs to address critical unmet needs in treating severely ill, hospitalized patients and in pediatric populations • Novel mechanisms of action • Combination therapy Our total reliance on monotherapy with NAI’s has placed us at risk of no treatment options to ASPR:address Resilient a potentialPeople. Healthy NAI- resistantCommunities. pandemic A Nation Prepared. 3 BARDA Influenza Therapeutics Program Line-Up • Two large, full development -
Enhancing the Astrocytic Clearance of Extracellular Α-Synuclein
Cellular and Molecular Neurobiology (2019) 39:1017–1028 https://doi.org/10.1007/s10571-019-00696-2 ORIGINAL RESEARCH Enhancing the Astrocytic Clearance of Extracellular α‑Synuclein Aggregates by Ginkgolides Attenuates Neural Cell Injury Jun Hua1,2 · Nuo Yin1 · Shi Xu1 · Qiang Chen1,3 · Tingting Tao1,3 · Ji Zhang4 · Jianhua Ding1 · Yi Fan1,3 · Gang Hu1,5 Received: 9 November 2018 / Accepted: 1 June 2019 / Published online: 5 June 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The accumulation of aggregated forms of the α-Synuclein (α-Syn) is associated with the pathogenesis of Parkinson’s dis- ease (PD), and the efcient clearance of aggregated α-Syn represents a potential approach in PD therapy. Astrocytes are the most numerous glia cells in the brain and play an essential role in supporting brain functions in PD state. In the present study, we demonstrated that cultured primary astrocytes engulfed and degraded extracellular aggregated recombinant human α-Syn. Meanwhile, we observed that the clearance of α-Syn by astrocytes was abolished by proteasome inhibitor MG132 and autophagy inhibitor 3-methyladenine (3MA). We further showed that intracellular α-Syn was reduced after ginkgolide B (GB) and bilobalide (BB) treatment, and the decrease was reversed by MG132 and 3MA. More importantly, GB and BB reduced indirect neurotoxicity to neurons induced by α-Syn-stimulated astrocytic conditioned medium. Together, we frstly fnd that astrocytes can engulf and degrade α-Syn aggregates via the proteasome and autophagy pathways, and further show that GB and BB enhance astrocytic clearance of α-Syn, which gives us an insight into the novel therapy for PD in future. -
Metabotropic Glutamate Receptor 5 Inhibits Α-Synuclein-Induced
Zhang et al. Journal of Neuroinflammation (2021) 18:23 https://doi.org/10.1186/s12974-021-02079-1 RESEARCH Open Access Metabotropic glutamate receptor 5 inhibits α-synuclein-induced microglia inflammation to protect from neurotoxicity in Parkinson’s disease Ya-Nan Zhang1, Jing-Kai Fan1,LiGu1, Hui-Min Yang1, Shu-Qin Zhan2,3 and Hong Zhang1* Abstract Background: Microglia activation induced by α-synuclein (α-syn) is one of the most important factors in Parkinson’s disease (PD) pathogenesis. However, the molecular mechanisms by which α-syn exerts neuroinflammation and neurotoxicity remain largely elusive. Targeting metabotropic glutamate receptor 5 (mGluR5) has been an attractive strategy to mediate microglia activation for neuroprotection, which might be an essential regulator to modulate α- syn-induced neuroinflammation for the treatment of PD. Here, we showed that mGluR5 inhibited α-syn-induced microglia inflammation to protect from neurotoxicity in vitro and in vivo. Methods: Co-immunoprecipitation assays were utilized to detect the interaction between mGluR5 and α-syn in microglia. Griess, ELISA, real-time PCR, western blotting, and immunofluorescence assays were used to detect the regulation of α-syn-induced inflammatory signaling, cytokine secretion, and lysosome-dependent degradation. Results: α-syn selectively interacted with mGluR5 but not mGluR3, and α-syn N terminal deletion region was essential for binding to mGluR5 in co-transfected HEK293T cells. The interaction between these two proteins was further detected in BV2 microglia, which was inhibited by the mGluR5 specific agonist CHPG without effect by its selective antagonist MTEP. Moreover, in both BV2 cells and primary microglia, activation of mGluR5 by CHPG partially inhibited α-syn-induced inflammatory signaling and cytokine secretion and also inhibited the microglia activation to protect from neurotoxicity. -
TLR4 Signaling Pathway Modulators As Potential Therapeutics in Inflammation and Sepsis
vaccines Review TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis Nikolay N. Kuzmich 1,2,*, Konstantin V. Sivak 1, Vladimir N. Chubarev 3, Yury B. Porozov 2,4, Tatiana N. Savateeva-Lyubimova 1 and Francesco Peri 5,* ID 1 Department of Drug Safety, Research Institute of Influenza, WHO National Influenza Centre of Russia, 15/17 Professor Popov St, Saint-Petersburg 197376, Russia; [email protected] (K.V.S.); [email protected] (T.N.S.-L.) 2 Laboratory of Bioinformatics, Institute of Pharmacy and Translational medicine, I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., Moscow 119991, Russia; [email protected] 3 Department of Pharmacology, Institute of Pharmacy and Translational medicine, I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., Moscow 119991, Russia; [email protected] 4 Laboratory of Bioinformatics, ITMO University, 49 Kronverkskiy Pr., Saint Petersburg 197101, Russia 5 Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, Milano 20126, Italy * Correspondence: [email protected] (N.N.K.); Tel.: +7-921-3491-750 (N.N.K.); [email protected] (F.P.); Tel.: +39-026-448-3453 (F.P.); Fax: +7-812-499-15-15 (N.N.K.) Academic Editor: Paola Massari Received: 5 September 2017; Accepted: 1 October 2017; Published: 4 October 2017 Abstract: Toll-Like Receptor 4 (TLR4) signal pathway plays an important role in initiating the innate immune response and its activation by bacterial endotoxin is responsible for chronic and acute inflammatory disorders that are becoming more and more frequent in developed countries.